Cargando…
Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration
We and others have shown that patients with different severity stages of age-related macular degeneration (AMD) have distinct plasma metabolomic profiles compared to controls. Urine is a biofluid that can be obtained non-invasively and, in other fields, urine metabolomics has been proposed as a feas...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874679/ https://www.ncbi.nlm.nih.gov/pubmed/35207212 http://dx.doi.org/10.3390/jcm11040940 |
_version_ | 1784657746626347008 |
---|---|
author | Lains, Ines Mendez, Kevin M. Gil, João Q. Miller, John B. Kelly, Rachel S. Barreto, Patrícia Kim, Ivana K. Vavvas, Demetrios G. Murta, Joaquim Neto Liang, Liming Silva, Rufino Miller, Joan W. Lasky-Su, Jessica Husain, Deeba |
author_facet | Lains, Ines Mendez, Kevin M. Gil, João Q. Miller, John B. Kelly, Rachel S. Barreto, Patrícia Kim, Ivana K. Vavvas, Demetrios G. Murta, Joaquim Neto Liang, Liming Silva, Rufino Miller, Joan W. Lasky-Su, Jessica Husain, Deeba |
author_sort | Lains, Ines |
collection | PubMed |
description | We and others have shown that patients with different severity stages of age-related macular degeneration (AMD) have distinct plasma metabolomic profiles compared to controls. Urine is a biofluid that can be obtained non-invasively and, in other fields, urine metabolomics has been proposed as a feasible alternative to plasma biomarkers. However, no studies have applied urinary mass spectrometry (MS) metabolomics to AMD. This study aimed to assess urinary metabolomic profiles of patients with different stages of AMD and a control group. We included two prospectively designed, multicenter, cross-sectional study cohorts: Boston, US (n = 185) and Coimbra, Portugal (n = 299). We collected fasting urine samples, which were used for metabolomic profiling (Ultrahigh Performance Liquid chromatography—Mass Spectrometry). Multivariable logistic and ordinal logistic regression models were used for analysis, accounting for gender, age, body mass index and use of AREDS supplementation. Results from both cohorts were then meta-analyzed. No significant differences in urine metabolites were seen when comparing patients with AMD and controls. When disease severity was considered as an outcome, six urinary metabolites differed significantly (p < 0.01). In particular, two of the metabolites identified have been previously shown by our group to also differ in the plasma of patients of AMD compared to controls and across severity stages. While there are fewer urinary metabolites associated with AMD than plasma metabolites, this study identified some differences across stages of disease that support previous work performed with plasma, thus highlighting the potential of these metabolites as future biomarkers for AMD. |
format | Online Article Text |
id | pubmed-8874679 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88746792022-02-26 Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration Lains, Ines Mendez, Kevin M. Gil, João Q. Miller, John B. Kelly, Rachel S. Barreto, Patrícia Kim, Ivana K. Vavvas, Demetrios G. Murta, Joaquim Neto Liang, Liming Silva, Rufino Miller, Joan W. Lasky-Su, Jessica Husain, Deeba J Clin Med Article We and others have shown that patients with different severity stages of age-related macular degeneration (AMD) have distinct plasma metabolomic profiles compared to controls. Urine is a biofluid that can be obtained non-invasively and, in other fields, urine metabolomics has been proposed as a feasible alternative to plasma biomarkers. However, no studies have applied urinary mass spectrometry (MS) metabolomics to AMD. This study aimed to assess urinary metabolomic profiles of patients with different stages of AMD and a control group. We included two prospectively designed, multicenter, cross-sectional study cohorts: Boston, US (n = 185) and Coimbra, Portugal (n = 299). We collected fasting urine samples, which were used for metabolomic profiling (Ultrahigh Performance Liquid chromatography—Mass Spectrometry). Multivariable logistic and ordinal logistic regression models were used for analysis, accounting for gender, age, body mass index and use of AREDS supplementation. Results from both cohorts were then meta-analyzed. No significant differences in urine metabolites were seen when comparing patients with AMD and controls. When disease severity was considered as an outcome, six urinary metabolites differed significantly (p < 0.01). In particular, two of the metabolites identified have been previously shown by our group to also differ in the plasma of patients of AMD compared to controls and across severity stages. While there are fewer urinary metabolites associated with AMD than plasma metabolites, this study identified some differences across stages of disease that support previous work performed with plasma, thus highlighting the potential of these metabolites as future biomarkers for AMD. MDPI 2022-02-11 /pmc/articles/PMC8874679/ /pubmed/35207212 http://dx.doi.org/10.3390/jcm11040940 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lains, Ines Mendez, Kevin M. Gil, João Q. Miller, John B. Kelly, Rachel S. Barreto, Patrícia Kim, Ivana K. Vavvas, Demetrios G. Murta, Joaquim Neto Liang, Liming Silva, Rufino Miller, Joan W. Lasky-Su, Jessica Husain, Deeba Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration |
title | Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration |
title_full | Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration |
title_fullStr | Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration |
title_full_unstemmed | Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration |
title_short | Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration |
title_sort | urinary mass spectrometry profiles in age-related macular degeneration |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874679/ https://www.ncbi.nlm.nih.gov/pubmed/35207212 http://dx.doi.org/10.3390/jcm11040940 |
work_keys_str_mv | AT lainsines urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT mendezkevinm urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT giljoaoq urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT millerjohnb urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT kellyrachels urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT barretopatricia urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT kimivanak urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT vavvasdemetriosg urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT murtajoaquimneto urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT liangliming urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT silvarufino urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT millerjoanw urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT laskysujessica urinarymassspectrometryprofilesinagerelatedmaculardegeneration AT husaindeeba urinarymassspectrometryprofilesinagerelatedmaculardegeneration |